Traditional Chinese medicine composition, medicine and preparation method and application thereof for preventing and treating type 2 diabetes osteoporosis
By preparing traditional Chinese medicine compositions containing epimedium, celestialis, celestialis, polygonatum, pueraria root and salvia, the problems of low content of active ingredients and poor bioavailability of existing traditional Chinese medicine compositions were solved, and osteoporosis of type 2 diabetes were significantly improved The therapeutic effect of the disease has improved the synergistic coordination between components and significantly improved bone density and bone strength.
Patent Information
- Application Number
- CN202411139587.4
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Filing Date
- 2024-08-20
- Publication Date
- 2024-11-08
- Estimated Expiration
- 2044-08-20
AI Technical Summary
The existing traditional Chinese medicine compositions are used to prevent and treat type 2 diabetes osteoporosis, which have problems with a wide variety of formula medicinal materials, low content of active ingredients, and poor bioavailability, resulting in unsatisfactory treatment results.
Provide a traditional Chinese medicine composition, including epimedium, celestialis, cypress pollen, polygonatum, pueraria root and salvia miltiorrhiza, is prepared by water extraction and alcohol solvent extraction methods to form a stable traditional Chinese medicine composition, and is combined with pharmaceutically acceptable auxiliary materials. Prepare into suitable dosage forms to improve utilization and stability.
The treatment effect of type 2 diabetes osteoporosis has been significantly improved. By improving the utilization rate and stability of the drug, the mutual coordination between components has been achieved, which has significantly improved the treatment effect. Animal experiments have shown that serum PTH, OCN, and PINP , CTX levels are elevated, pathology of proximal femoral bone tissue is improved, and bone density and strength are increased.
Smart Images

Figure CN118649210B_ABST
Abstract
Description
Technical Field
[0001] The present invention relates to the technical field of traditional Chinese medicines, and in particular to a traditional Chinese medicine composition, a medicine and a preparation method and application thereof for preventing and treating type 2 diabetes osteoporosis. Background Art
[0002] Diabetic osteoporosis (DOP) is a skeletal complication caused by diabetes. It is a secondary osteoporosis characterized by decreased bone mineral density (BMD), changes in bone microstructure, and increased bone fragility. It has the characteristics of high morbidity and high disability rate. Osteoporosis and diabetes are chronic diseases with significant associated morbidity and mortality. Current studies have shown that both type 1 and type 2 diabetes are associated with an increased risk of fractures. Fractures, as a complication of diabetes, must be considered when evaluating and treating diabetic patients. DOP increases the risk of fractures, and the resulting long-term inactivity and hospitalization can lead to increased morbidity and mortality. In patients with type 1 diabetes, bone mass and bone strength are reduced, resulting in a 5-fold increase in the risk of fractures throughout life; in patients with type 2 diabetes, the risk of fractures is increased despite normal bone mass.
[0003] Regarding the measures to prevent or treat osteoporosis in type 2 diabetes, lifestyle, including appropriate physical activity, smoking cessation, avoiding alcohol abuse and ensuring adequate dietary calcium and vitamin D intake, should be the main means of preventing and treating osteoporosis in type 2 diabetes. Maintaining good blood sugar control and avoiding hypoglycemia can reduce the risk of fractures. Traditional Chinese medicine has shown great therapeutic potential in the treatment of DOP. It can not only achieve clinical therapeutic effects through multiple pathways and multiple targets, but also has the advantages of few adverse reactions, high compliance and moderate price.
[0004] Chinese patent CN115400184A discloses a Chinese medicine composition for treating osteoporosis complicated by diabetes, comprising the following raw materials: psoralea corylifolia, epimedium, drynaria, eucommia bark, dodder seed, antler glue, cornus officinalis, yam, codonopsis pilosula, atractylodes macrocephala, gentiana macrophylla, notopterygium wilfordii, angelica pubescens, prepared rehmannia root, astragalus, safflower, salvia miltiorrhiza. With "kidney deficiency, liver and spleen deficiency, dampness and blood stasis" as the pathogenesis, on the basis of "liver and kidney are homologous, kidney governs bones": tonifying the kidney is the main method, taking into account the liver and spleen, tonifying the kidney promotes bone strength, regulating the liver and spleen, nourishing the innate by the acquired, promoting the biochemical and transportation of qi and blood, and nourishing the five internal organs; expelling wind, cold, dampness and arthralgia, qi deficiency and blood stasis blocking the collaterals, achieving pain-free, adding drugs for tonifying qi and deficiency, nourishing the whole body, and being particularly good for patients with osteoporosis complicated by diabetes.
[0005] Chinese patent CN105749179A discloses a Chinese medicine composition for treating metabolic syndrome, which is composed of the following components: angelica, notoginseng, ginseng, oriental rhizome, lotus leaf, ebony, gynostemma pentaphyllum, cassia seed, allium macrostemon, cinnamon twig, immature bitter orange, salvia miltiorrhiza, coptis root, hawthorn, cactus, radish seed, litchi seed, astragalus, aloe, tuckahoe, stephania tetrandra, cinnamon bark, pangolin, curcuma, motherwort, amomum villosum, kudzu root, wolfberry leaf, bupleurum, radix rehmanniae, cornus, yam, radix trichosanthis, epimedium, strychnos nux vomica, plantago seed, etc. The compatibility of the various drugs in the invention complements each other and can be effectively used for syndrome differentiation and treatment of metabolic syndrome, improving blood lipid levels, and reducing insulin resistance and obesity.
[0006] Current Chinese medicine compositions generally have problems such as a wide variety of formula medicinal materials, low content of active ingredients, and poor bioavailability. Summary of the invention
[0007] In view of this, the purpose of the present invention is to provide a composition for preventing and treating osteoporosis in type 2 diabetes, in which the components cooperate with each other, the utilization rate of the drug is high and the stability is good, and the therapeutic effect on osteoporosis in type 2 diabetes can be significantly improved.
[0008] To achieve the above-mentioned purpose of the invention, the technical solution of the present invention is as follows:
[0009] On the one hand, the present invention provides a traditional Chinese medicine composition for preventing and treating osteoporosis in type 2 diabetes, which is prepared from the following raw materials by weight: 10-20 parts of epimedium, 10-15 parts of curculigo, 5-15 parts of trichosanthes, 25-35 parts of polygonatum, 10-15 parts of kudzu root, 5-12 parts of rhodiola rosea and 10-20 parts of salvia miltiorrhiza.
[0010] In the formula of the present invention, Epimedium and Curculigo are used together as the main medicine, which can specifically nourish the kidney and strengthen the bones, and the two are often used as a "pair of medicines" in clinical practice to nourish the kidney and strengthen yang, strengthen the tendons and bones; Radix Trichosanthis and Polygonatum sibiricum are the assistant medicines, which can specifically clear away heat and purge fire, nourish yin and promote the production of body fluid, and the two are often used as a "pair of medicines" in clinical practice to treat diabetes; Radix Puerariae and Rhodiola rosea are the adjuvant medicines, which can nourish yin, lower blood sugar and relieve severe symptoms; the auxiliary medicine Salvia miltiorrhiza can activate blood circulation and dredge collaterals; the whole formula has the effects of nourishing the kidney and strengthening bones, activating blood circulation and dredge collaterals.
[0011] Preferably, the Chinese medicine composition is made of the following raw materials by weight: 12-16 parts of Epimedium, 10-12 parts of Curculigo, 8-12 parts of Radix Trichosanthis, 28-32 parts of Polygonatum, 10-13 parts of Pueraria, 8-12 parts of Rhodiola and 10-15 parts of Salvia miltiorrhiza.
[0012] Further preferably, the Chinese medicine composition is made of the following raw materials, by weight: 15 parts of Epimedium, 12 parts of Curculigo, 10 parts of Radix Trichosanthis, 30 parts of Polygonatum, 12 parts of Pueraria, 10 parts of Rhodiola and 12 parts of Salvia miltiorrhiza.
[0013] In another aspect, the present invention provides a method for preparing the above-mentioned Chinese medicine composition, comprising the steps of:
[0014] (1) extracting the formulated raw materials with water, removing the residue, and concentrating to obtain a concentrate;
[0015] (2) Extracting the concentrate with an alcohol solvent to obtain a Chinese medicine composition.
[0016] Preferably, in step (1), the extraction method is selected from any one of decoction extraction and reflux extraction.
[0017] Preferably, in step (1), the weight of the water added is 8-12 times the weight of the raw material, and more preferably 10 times.
[0018] Preferably, in step (2), the alcohol solvent is selected from at least one of methanol, ethanol, propanol and butanol; more preferably, it is at least one of methanol and ethanol.
[0019] Preferably, in step (2), the extraction conditions are: solid-liquid ratio 1:8-12, unit is g:mL; temperature 80-100°C; time 1-3h. More preferably: solid-liquid ratio 1:10, unit is g:mL; temperature 100°C; time 2h.
[0020] In another aspect, the present invention provides a medicine comprising the above-mentioned Chinese medicine composition and pharmaceutically acceptable excipients.
[0021] The dosage form of the drug is selected from pills, capsules, granules, oral liquids, powders, tablets, lozenges and other dosage forms, and suitable drug carriers in the art can be selected for different dosage forms.
[0022] The pharmaceutical carrier used can be solid, liquid or gas. Examples of solid carriers include lactose, kaolin, sucrose, talc, gelatin, agar, pectin, gum arabic, magnesium stearate and stearic acid. Examples of liquid carriers include syrup, peanut oil, olive oil and water. Examples of gaseous carriers include carbon dioxide and nitrogen.
[0023] When preparing the composition for oral dosage form, any convenient pharmaceutical medium may be used. For example, water, ethanol, oil, alcohol, flavoring agents, preservatives, colorants, etc. may be used to form oral liquid preparations such as suspensions and solutions; and carriers such as starch, sugars, microcrystalline cellulose, diluents, granulating agents, emulsifiers, lubricants, binders, disintegrants may be used to form oral solid preparations, such as powders, capsules, and tablets. Tablets may be coated using standard aqueous or non-aqueous techniques.
[0024] Tablets containing the Chinese medicine composition of the present invention can be prepared by tableting or molding, and one or more auxiliary ingredients or adjuvants can be used. The active ingredient can be tableted in a free-flowing form (such as powder or granules) in an appropriate machine, and can be prepared by mixing with an adhesive, a lubricant, an inert diluent, a surfactant, and a dispersant. Molded tablets can be molded in an appropriate machine. Each tablet preferably contains about 0.05 mg to about 5 g of active ingredient, and each sachet or capsule preferably contains about 0.05 mg to about 5 g of active ingredient. For example, a preparation intended for oral administration to the human body may contain about 0.5 mg to about 5 g of active drug, mixed with an appropriate and convenient carrier material, which may account for about 5% to 95% of the total composition. The unit dosage form usually contains about 1 mg to about 2 g of active ingredient, usually 25 mg, 50 mg, 100 mg, 200 mg, 300 mg, 400 mg, 500 mg, 600 mg, 800 mg or 1000 mg.
[0025] The medicine of the present invention can also be in a form suitable for rectal administration, wherein the carrier is a solid. Preferably, the mixture is made into a unit dose suppository. Suitable carriers include cocoa butter and other materials commonly used in the art. Suppositories can be prepared by first forming a composition containing a softened or melted carrier, followed by cooling and shaping in a mold.
[0026] In addition to the above-mentioned carrier components, the above-mentioned pharmaceutical preparations may include (if applicable) one or more additional carrier components, such as diluents, buffers, flavoring agents, binders, surfactants, thickeners, lubricants, preservatives (including antioxidants), etc. In addition, other excipients may be added, such as lactose, starch, cellulose derivatives, magnesium stearate, stearic acid, colorants and flavoring agents, etc.
[0027] Preferably, the drug is in the form of granules.
[0028] In another aspect, the present invention provides a method for preparing the above-mentioned drug, comprising the steps of:
[0029] (1) extracting the formulated raw materials with water, removing the residue, and concentrating to obtain a concentrate;
[0030] (2) extracting the concentrate with an alcohol solvent to obtain a Chinese medicine composition;
[0031] (3) The Chinese medicine composition is mixed with soluble starch, lactose and a wetting agent to prepare a soft material, granulated and dried.
[0032] Preferably, in step (1), the extraction method is selected from any one of decoction extraction and reflux extraction.
[0033] Preferably, in step (1), the weight of the water added is 8-12 times the weight of the raw material, and more preferably 10 times.
[0034] Preferably, in step (2), the alcohol solvent is selected from at least one of methanol, ethanol, propanol and butanol; more preferably, it is at least one of methanol and ethanol.
[0035] Preferably, in step (2), the extraction conditions are: solid-liquid ratio 1:8-12, unit is g:mL, temperature 80-100°C, time 1-3h. More preferably: solid-liquid ratio 1:10, unit is g:mL, temperature 100°C, time 2h.
[0036] Preferably, step (3) is specifically as follows: the Chinese medicine composition is mixed with soluble starch and lactose for 10 minutes, 85% ethanol is added as a wetting agent, the material is softened and then granulated, and dried at 65° C. for 4 hours.
[0037] Further preferably, the mass ratio of the soluble starch to lactose is 2-4:1, and further preferably is 3:1.
[0038] Finally, the present invention provides the use of the above-mentioned Chinese medicine composition or the above-mentioned medicine in the preparation of a medicine for treating osteoporosis in type 2 diabetes.
[0039] Preferably, the treatment of type 2 diabetes osteoporosis includes: improving sugar metabolism levels, promoting osteogenesis, increasing bone density and reducing bone microstructural damage.
[0040] The beneficial effects of the present invention are:
[0041] (1) By controlling the specific types and ratios of drugs, the utilization rate of the drugs is high and their stability is good, achieving the synergistic effect between the components and improving the effect of treating osteoporosis in type 2 diabetes.
[0042] (2) Animal experiments showed that the Chinese medicine composition of the present invention increased the levels of serum PTH, OCN, PINP, and CTX; significantly improved the pathology of proximal femoral bone tissue; improved the microstructure of Micro-CT bone tissue, increased bone density, and increased bone strength. BRIEF DESCRIPTION OF THE DRAWINGS
[0043] Figure 1 The histopathological images of rats in each group;
[0044] Figure 2 Micro-CT scans (sagittal) of the femoral metaphysis of rats in each group;
[0045] Figure 3 Micro-CT scans (cross-sectional views) of the femoral metaphysis of rats in each group.
[0046] in, Figure 1-Figure 3In the figure, A is the normal group; B is the model group; C is the metformin group; D, E, and F correspond to the low-dose group of Example 1, the medium-dose group of Example 1, and the high-dose group of Example 1, respectively. DETAILED DESCRIPTION
[0047] The following non-limiting examples can enable those skilled in the art to more fully understand the present invention, but do not limit the present invention in any way. The following content is only an exemplary description of the scope of the present invention, and those skilled in the art can make various changes and modifications to the invention of the present invention based on the disclosed content, and they should also fall within the scope of the present application.
[0048] The present invention is further described below by way of specific examples. The various chemical reagents used in the examples of the present invention are obtained through conventional commercial channels unless otherwise specified. Unless otherwise specified, the contents described below are all weight contents. Unless otherwise specified, it is understood that the process is carried out at room temperature.
[0049] Example 1
[0050] Formula: 15 parts of Epimedium, 12 parts of Curculigo, 10 parts of Radix Trichosanthis, 30 parts of Polygonatum, 12 parts of Pueraria, 10 parts of Rhodiola and 12 parts of Salvia miltiorrhiza.
[0051] Example 2
[0052] Formula: 12 parts of Epimedium, 10 parts of Curculigo, 12 parts of Radix Trichosanthis, 32 parts of Polygonatum, 13 parts of Pueraria, 8 parts of Rhodiola and 10 parts of Salvia miltiorrhiza.
[0053] Example 3
[0054] Formula: 16 parts of Epimedium, 12 parts of Curculigo, 8 parts of Radix Trichosanthis, 28 parts of Polygonatum, 10 parts of Pueraria, 12 parts of Rhodiola and 15 parts of Salvia miltiorrhiza.
[0055] Comparative Example 1
[0056] The difference from Example 1 is that Curculigo is replaced with the same amount of Drynariae Rhizoma, and the rest are the same.
[0057] Comparative Example 2
[0058] The difference from Example 1 is that Salvia miltiorrhiza is replaced by the same amount of Psoralea corylifolia, and the rest are the same.
[0059] Comparative Example 3
[0060] Recipe: 12 parts of Curculigo, 30 parts of Polygonatum, 12 parts of Pueraria and 12 parts of Salvia miltiorrhiza.
[0061] Comparative Example 4
[0062] Formula: 15 parts of Epimedium, 10 parts of Radix Trichosanthis, 10 parts of Rhodiola and 12 parts of Salvia miltiorrhiza.
[0063] Comparative Example 5
[0064] 25 parts of Epimedium, 20 parts of Curculigo, 20 parts of Radix Trichosanthis, 15 parts of Polygonatum, 5 parts of Pueraria, 5 parts of Rhodiola and 25 parts of Salvia miltiorrhiza.
[0065] Preparation Example
[0066] The compositions of the embodiments and comparative examples were prepared into granules according to the following method:
[0067] Weigh epimedium, curculigo, radix trichosanthis, polygonatum, kudzu root, rhodiola rosea, and salvia miltiorrhiza according to the prescription amount, add 10 times the weight of the total weight of the medicinal materials, decoct twice, each time for 2 hours, combine the decoction, filter, and concentrate the filtered liquid into a thick paste (density 1.38g / cm 3 ), the thick paste was extracted with an alcohol solvent, and the extraction conditions were: solid-liquid ratio 1:10 (g:mL), temperature 100°C, time 2h, to obtain a Chinese medicine composition.
[0068] The obtained Chinese medicine composition is completely freed of ethanol and prepared into granules in a conventional manner. Specifically, in the present invention, the Chinese medicine composition is prepared into granules according to the following steps:
[0069] The obtained traditional Chinese medicine composition was dried under reduced pressure and vacuum at 65°C to completely remove the solvent to obtain a dry extract. The dry extract powder was obtained after passing through a 110-mesh sieve, and soluble starch and lactose (mass ratio 3:1) were added, and the ratio of the total mass of soluble starch and lactose to the mass of the dry extract powder was 1:1.5. The mixture was mixed for 10 minutes, and an appropriate amount of 85% ethanol was added as a wetting agent. The mixture was softened and then granulated. The mixture was dried at 65°C for 4 hours, and the granules were prepared.
[0070] Effect test
[0071] 1. Experimental reagents and instruments
[0072] The granules prepared by the formula of the embodiment and the comparative example were prepared with deionized water before the experiment, and then completely dissolved by ultrasonic treatment for 50 minutes, and then stored at 4°C). Metformin hydrochloride tablets (Shanghai Bristol-Myers Squibb Pharmaceuticals Co., Ltd., China, 0.5 g, 20 tablets / box, item number H20023370).
[0073] Insulin kit, AGEs kit, IGF-1 kit, OCN kit, P1NP kit, CTX kit, and PTH kit are all from Beijing Huaying Institute of Biotechnology, with catalog numbers 20211015, 20210928, 20211015, 20211011, 20211018, 20211018, and 20211018, respectively.
[0074] ARKRAY blood glucose meter, ARKRAY Japan Co., Ltd., model GT-1941; MicroCT, Bruker Corporation, USA, model Skyscan1276; Bone densitometer, MEDILINK, France, model OSTEOCORE3.
[0075] The experimental animals were ZDF rats (type 2 diabetic rats), among which ZDF (fa / fa) were type 2 diabetic model rats and ZDF (fa / +) were type 2 diabetic control rats.
[0076] 2. Experimental methods
[0077] 2.1 Animal grouping: After the ZDF (fa / fa) rats were modeled, random stratified sampling was used according to blood sugar and body weight, with 8 rats in each group. They were model group, metformin hydrochloride group, high group of Example 1, medium group of Example 1, low group of Example 1, Example 2 group, Example 3 group, comparative example 1 group, comparative example 2 group, comparative example 3 group, comparative example 4 group, and comparative example 5 group (Example 2-Example 3, Comparative Example 1-Comparative Example 5 all use the dose of the high group of Example 1). 8 ZDF (fa / +) rats of the same age were set as the normal control group. Dosage: The reference dose of metformin hydrochloride was 0.135 g / kg; the doses of the high group, medium group, and low group of Chinese medicine granules were 2.5 g / kg, 1.25 g / kg, and 0.625 g / kg, respectively; the model group and the normal group were gavaged with equal volumes of deionized water for 12 consecutive weeks.
[0078] 2.2 Modeling method
[0079] After 1 week of adaptive feeding, the control rats were given a regular diet, and the remaining rats were given 5008 special diet (formula: crude protein 23.5%, crude fat 6.5%) for 4 weeks. 5008 special diet was provided by Sibeifu (Beijing) Biotechnology Co., Ltd., batch number 20210414. Male ZDF (fa / fa) rats spontaneously developed T2DM at 11 weeks of age.
[0080] 3. Results
[0081] 3.1 Effects of Chinese herbal compound granules on glucose metabolism
[0082] Detection method: Rats in each group fasted for 12 h at the same time point in the morning every 4 weeks, and their fasting blood glucose (FBG) was measured by blood sampling from the tail tip vein. Enzyme immunoassay was used to measure the levels of fasting serum insulin (FINS), insulin-like growth factor 1 (IGF-1), and advanced glycation end products (AGEs); and the insulin resistance index (HOMA-IR) was calculated:
[0083] HOMA-IR=FBG×FINS÷22.5.
[0084] The results are as follows:
[0085] Table 1. Fasting blood glucose test results of ZDF rats in each group, unit: mmol / L
[0086]
[0087] Note: #Compared between model group and normal group, P<0.05, ##Compared between model group and normal group, P<0.01; *Compared with model group, P<0.05, **Compared with model group, P<0.01.
[0088] Table 2. Effects on blood glucose metabolism in ZDF rats of each group
[0089]
[0090] Note: #Compared between model group and normal group, P<0.05, ##Compared between model group and normal group, P<0.01; *Compared with model group, P<0.05, **Compared with model group, P<0.01.
[0091] 3.2 Effects of Chinese herbal compound granules on bone metabolism
[0092] The serum bone metabolism indexes of rats including osteocalcin (OCN), type I procollagen amino terminal peptide (PINP), type I collagen crosslinked C-terminal peptide (CTX) and parathyroid hormone (PTH) were detected.
[0093] The results are as follows:
[0094] Table 3. Effects on bone metabolism of ZDF rats in each group
[0095]
[0096] Note: #Compared between model group and normal group, P<0.05, ##Compared between model group and normal group, P<0.01; *Compared with model group, P<0.05, **Compared with model group, P<0.01.
[0097] 3.3 Effect of Chinese herbal medicine on lumbar spine and left femoral bone mineral density
[0098] Detection method: (1) The rats to be tested were anesthetized by isoflurane inhalation anesthesia using a small animal anesthesia machine; (2) The flow rate of the anesthesia machine and the anesthesia time were set as follows: the flow rate was set to 4-4.5 L / h, and the anesthesia time was 2 minutes and 30 seconds; (3) The anesthetized rats were temporarily fixed with rubber bands at the head and tail ends, and the rats were placed in a supine position on a fixed board on the bone densitometer examination bed; (4) After the image was taken, the bone density interest area was selected: lumbar vertebrae 2-4 and proximal femur, for scanning and data analysis.
[0099] The results are as follows:
[0100] Table 4. Effects on BMD of ZDF rats in each group, unit: g / cm 2
[0101]
[0102] Note: #Compared between model group and normal group, P<0.05, ##Compared between model group and normal group, P<0.01; *Compared with model group, P<0.05, **Compared with model group, P<0.01.
[0103] The results in Tables 1 to 4 show that the composition of the present invention can affect blood glucose metabolism to varying degrees, reduce FBG, FINS, IGF-1, AGEs levels and HOMA-IR, and can improve bone metabolism, lumbar spine and left femoral bone density in ZDF rats to varying degrees.
[0104] 3.4. Effects of Chinese herbal medicine on bone microstructure
[0105] Figure 1-Figure 3 The results showed that the trabecular bone network of the femoral head tissue of the normal group rats was dense and regular. Compared with the normal group, the trabecular bone width of the femoral head tissue of the model group rats became narrower and discontinuous, the distance between the trabeculae widened, and the reticular structure did not exist. Compared with the bone tissue of the model group rats, the intervention of the metformin group and the Chinese medicine compound group significantly improved the normal morphological structure of the trabeculae and showed an orderly distribution of the reticular network. The morphology and structure of the bone tissue of the metformin group and the high-dose Chinese medicine compound group were similar to those of the normal group.
[0106] In summary, the Chinese medicine composition of the present invention can effectively improve the glucose metabolism level of rats with type 2 diabetes, promote osteogenesis, increase bone density, and reduce bone microstructural damage in rats with type 2 diabetes, indicating that the Chinese medicine compound prepared by the present application can effectively treat osteoporosis in type 2 diabetes. Comparative Examples 1-2 show that the present invention selects a specific combination of 10 ingredients, which can significantly improve the therapeutic effect on type 2 diabetes compared to replacing them with similar ingredients. The results of Comparative Examples 3-4 show that under the same dosage, the effect of some ingredients after combination is not ideal, while the effect is significantly improved after combination. Comparative Example 5 shows that the prescription of the present invention achieves a good synergistic therapeutic effect under a specific ratio.
[0107] The present invention achieves the synergistic effect between components by controlling the specific types and proportions of drugs, thereby significantly improving the therapeutic effect of treating type 2 diabetes osteoporosis.
[0108] The above description is only a preferred embodiment of the present invention and is not intended to limit the present invention. Any modifications, equivalent substitutions, improvements, etc. made within the spirit and principle of the present invention should be included in the protection scope of the present invention.
Claims
1. A Chinese medicine composition for preventing and treating type 2 diabetes osteoporosis, characterized in that: The invention is prepared from the following raw materials by weight: 10-20 parts of epimedium, 10-15 parts of curculigo, 5-15 parts of trichosanthes, 25-35 parts of polygonatum, 10-15 parts of kudzu root, 5-12 parts of rhodiola rosea and 10-20 parts of salvia miltiorrhiza.
2. The Chinese medicine composition according to claim 1, characterized in that: The invention is prepared from the following raw materials by weight: 12-16 parts of epimedium, 10-12 parts of curculigo, 8-12 parts of trichosanthes, 28-32 parts of polygonatum, 10-13 parts of kudzu root, 8-12 parts of rhodiola rosea and 10-15 parts of salvia miltiorrhiza.
3. The Chinese medicine composition according to claim 2, characterized in that: The invention is prepared from the following raw materials by weight: 15 parts of epimedium, 12 parts of curculigo, 10 parts of trichosanthes, 30 parts of polygonatum, 12 parts of kudzu root, 10 parts of rhodiola rosea and 12 parts of salvia miltiorrhiza.
4. The method for preparing the Chinese medicine composition according to any one of claims 1 to 3, characterized in that: Includes steps: (1) extracting the formulated raw materials with water, removing the residue, and concentrating to obtain a concentrate; (2) Extracting the concentrate with an alcohol solvent to obtain a Chinese medicine composition.
5. The preparation method according to claim 4, characterized in that: In step (2), the extraction conditions are: solid-liquid ratio 1:8-12, unit is g:mL; temperature 80-100°C; time 1-3h.
6. A drug, characterized in that The invention comprises the Chinese medicine composition according to any one of claims 1 to 3 and pharmaceutically acceptable excipients.
7. The drug according to claim 6, characterized in that The dosage form of the drug is selected from any one of pills, capsules, granules, oral liquids, powders, tablets and lozenges.
8. The drug according to claim 7, characterized in that The dosage form of the medicine is granules.
9. The method for preparing the drug according to claim 8, characterized in that: Includes steps: (1) extracting the formulated raw materials with water, removing the residue, and concentrating to obtain a concentrate; (2) extracting the concentrate with an alcohol solvent to obtain a Chinese medicine composition; (3) Adding powdered sugar and dextrin to the Chinese medicine composition, sieving, making granules, and drying.
10. Use of the Chinese medicine composition according to any one of claims 1 to 3 or the medicine according to any one of claims 6 to 8 in the preparation of a medicine for treating osteoporosis in type 2 diabetes.
